Describir: Prognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine–Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.